# 缓激肽介导的血管性水肿市场

> 布拉迪激肽介导的血管性水肿市场研究报告按类型（遗传性血管性水肿、获得性血管性水肿、特发性血管性水肿）、按治疗选项（C1抑制剂替代疗法、布拉迪激肽B2受体拮抗剂、卡利纳特疗法、抗纤溶药物）、按给药途径（皮下、静脉内、口服）、按患者人口统计（儿童患者、成人患者、老年患者）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测至2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.62%
- **2024:** $ 1.15 Billion
- **2025:** $ 1.29 Billion
- **2035:** $ 3.87 Billion
- **Key Players:** Takeda Pharmaceutical Company Limited (JP), CSL Behring LLC (US), Pharming Group N.V. (NL), Sobi AB (SE), BioCryst Pharmaceuticals, Inc. (US), Eisai Co., Ltd. (JP), Grifols S.A. (ES), Amgen Inc. (US)

**Report ID:** MRFR/HC/34260-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/bradykinin-mediated-angioedema-market-36162

---

## Market Summary

## **Bradykinin Mediated Angioedema Market Overview**

As per MRFR analysis, the Bradykinin Mediated Angioedema Market Size was estimated at 1.15 (USD Billion) in 2024. The Bradykinin Mediated Angioedema Market Industry is expected to grow from 1.29 (USD Billion) in 2025 to 3.47 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 11.62% during the forecast period (2025 - 2034).

### **Key Bradykinin Mediated Angioedema Market Trends Highlighted**

The Bradykinin Mediated Angioedema Market is significantly influenced by several key market drivers. An increasing awareness of the disorder has led to a rise in early diagnosis and treatment options. Enhancements in medical research have improved the understanding of angioedema, promoting the development of targeted therapies. Additionally, the growing prevalence of underlying conditions such as hereditary angioedema and increased access to healthcare services are facilitating market expansion. Pharmaceutical advancements are also pushing the boundaries of treatment modalities, further driving the market. Opportunities in this market are abundant, particularly in the development of innovative therapies and products targeting various patient demographics.

The rise of personalized medicine opens new avenues for customized treatment solutions. Collaborations between pharmaceutical companies and research institutions can accelerate drug discovery processes. Expanding geographical presence in emerging markets represents another significant opportunity, as these regions often have unmet medical needs and a growing patient population. The establishment of educational programs focused on angioedema can help in raising awareness, leading to better patient outcomes and market growth. In recent times, there has been a noticeable trend towards the development of biologic drugs, which are showing promise in effectively managing symptoms of bradykinin-mediated angioedema.

Advancements in biotechnology are contributing to this trend, along with a shift toward chronic disease management models. Digital health solutions, including telemedicine and mobile applications for monitoring symptoms, are gaining traction. These trends indicate a shift in how healthcare is delivered, making it more accessible and patient-centered. As the market evolves, these dynamics will likely shape its future direction, offering new potential pathways for growth and innovation.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Bradykinin Mediated Angioedema Market Drivers**

### **Increasing Awareness and Diagnosis of Bradykinin Mediated Angioedema**

As the prevalence of bradykinin mediated angioedema becomes more recognized, both healthcare providers and patients are gaining a better understanding of this condition. There has been an evident shift towards improving diagnosis rates, identifying symptoms early, and advocating for timely treatment. Enhanced education and awareness campaigns from health organizations contribute significantly to this shift. As medical professionals become more informed about the various manifestations of angioedema, they are better equipped to identify bradykinin mediated cases.

This growing awareness extends to patients, who are increasingly educated about their conditions through support groups, online resources, and healthcare platforms. Consequently, more individuals are seeking medical advice, leading to a higher rate of diagnosis and treatment. This trend is a crucial driver for the Bradykinin Mediated Angioedema Market Industry as it translates into increased demand for healthcare services, diagnostic tools, and effective therapies.

With more patients being diagnosed, pharmaceutical companies are prompted to invest in the development of specialized medications, further fueling market growth. The heightened focus on research and development to understand the pathophysiological mechanisms underlying this condition is also pivotal. Importantly, as more advancements are made in treatments, physicians are likely to prescribe these innovative solutions, which will be highly beneficial for patient outcomes.

Thus, increasing awareness not only plays a key role in patient diagnosis but also drives the innovation and growth of the Bradykinin Mediated Angioedema Market Industry, fostering a cycle that enhances overall healthcare standards and improves life quality for patients experiencing this condition.

### **Technological Advancements in Pharmaceutical Development**

The Bradykinin Mediated Angioedema Market Industry is significantly benefiting from profound advancements in technology, particularly in pharmaceutical research and product development. Innovations in biotechnology and drug formulation techniques have led to the introduction of more effective treatments for bradykinin mediated angioedema, enhancing patient care. The development of monoclonal antibodies, small molecules, and new biologics specifically targeting the underlying mechanisms of bradykinin release exemplifies the forward momentum in this field.

Furthermore, improved drug delivery systems are ensuring better patient compliance and therapeutic outcomes, making these treatments more accessible and efficient. Such technological breakthroughs are vital in expanding the available treatment options, which, in turn, supports the growth of the Bradykinin Mediated Angioedema Market.

### **Rising Incidence of Angioedema Cases**

The growing incidence of angioedema cases globally is a major driver for the Bradykinin Mediated Angioedema Market Industry. Factors such as environmental changes, dietary habits, and increased exposure to allergens contribute to the rise in cases. This upward trend necessitates enhanced healthcare initiatives, expanding the market for targeted therapies and treatments for patients suffering from this condition. As more individuals experience symptoms and seek medical assistance, healthcare providers are more inclined to focus on providing effective solutions, leading to market growth.

## ** ****Bradykinin Mediated Angioedema Market Segment Insights**

### **Bradykinin Mediated Angioedema Market Type Insights**

The Bradykinin Mediated Angioedema Market is witnessing significant growth, with a market valuation of 0.93 USD Billion in 2023 and expected to reach 2.5 USD Billion by 2032, driven by rising awareness and improved diagnostics. The market segmentation around Type prominently features Hereditary Angioedema, Acquired Angioedema, and Idiopathic Angioedema. Among these, [Hereditary Angioedema](../../../reports/hereditary-angioedema-therapeutics-market-12163) holds a majority market share, valued at 0.4 USD Billion in 2023, and is projected to grow substantially to 1.05 USD Billion by 2032, highlighting its dominance due to genetic predispositions and increasing patient identification.

This sub-segment is particularly significant as it emphasizes the need for targeted therapies and ongoing patient management strategies. Acquired Angioedema, while smaller in comparison, reflects a substantial market presence, with a valuation of 0.3 USD Billion in 2023 and expected growth to 0.8 USD Billion by 2032. The challenges surrounding the identification of triggers and underlying conditions contribute to its relevance in the market, making the development of therapeutic options increasingly important. Lastly, Idiopathic Angioedema, which accounted for 0.23 USD Billion in 2023 and aims for a future valuation of 0.65 USD Billion, is the least dominant type.

However, it presents unique challenges due to its unpredictable nature, leading to a notable opportunity for pharmaceutical advancements and improved treatment strategies. The Bradykinin Mediated Angioedema Market data reflects a balanced yet complex interplay of these segments, with varying growth drivers, including heightened research initiatives and patient advocacy groups fostering a conducive environment for market expansion. Understanding this market segmentation allows stakeholders to tailor their approaches to meet the varying needs of each type effectively while capitalizing on the growth potential and complexities inherent in the treatment landscape.

As such, the industry faces opportunities and challenges that influence the development of effective therapies tailored for specific Angioedema types, ensuring that patient outcomes continue to improve as the market evolves.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Bradykinin Mediated Angioedema Market Treatment Options Insights**

The Bradykinin Mediated Angioedema Market, focusing on Treatment Options, shows a robust growth trajectory, with the market valued at 0.93 billion USD in 2023. By 2032, this market is expected to grow significantly. The Treatment Options segment is driven by an increasing prevalence of Bradykinin Mediated Angioedema, with key therapies such as C1-Inhibitor Replacement Therapy playing a pivotal role owing to its effectiveness in managing acute attacks. Bradykinin B2 Receptor Antagonists are also essential, showcasing a significant demand due to their targeted action in slowing down symptoms related to angioedema.

Additionally, Kalinate Therapy is garnering attention as it presents opportunities for enhanced patient outcomes. Antifibrinolytic Agents remain crucial within this market, offering therapeutic benefits that complement other treatment modalities. Overall, the Bradykinin Mediated Angioedema Market revenue illustrates a clear alignment between growing treatment needs and innovative drug development strategies, emphasizing the importance of each therapy in providing effective management of the disorder amidst evolving patient care standards.

### **Bradykinin Mediated Angioedema Market Route of Administration Insights**

The Bradykinin Mediated Angioedema Market is experiencing significant growth, particularly in the Route of Administration segment, which plays a critical role in treatment efficacy and patient compliance. In 2023, the market was valued at 0.93 billion USD and is projected to expand substantially in the coming years. The market sees a strong emphasis on various methods of administration, including Subcutaneous, Intravenous, and Oral, each catering to different patient needs. Subcutaneous administration is noted for its ease of use and ability to improve patient adherence, making it a preferred choice among healthcare providers.

Intravenous administration, albeit less common, offers rapid action for acute cases and is vital in clinical settings. The Oral route, with its convenience and patient-friendly nature, continues to gain traction, appealing particularly to home care settings. These various routes contribute to the segmentation of the Bradykinin Mediated Angioedema Market, which is crucial for targeted therapies tailored to individual patient profiles. The growth in this segment is driven by an increasing prevalence of bradykinin-mediated conditions, evolving treatment paradigms, and ongoing research into improving administration methods while enhancing patient experience and outcomes.

The Bradykinin Mediated Angioedema Market data reveals promising trends around these administration routes, highlighting their potential to meet diverse healthcare needs.

### **Bradykinin Mediated Angioedema Market Patient Demographics Insights**

The Bradykinin Mediated Angioedema Market, valued at 0.93 billion USD in 2023, showcases a diverse Patient Demographics segment that includes Pediatric, Adult, and Geriatric Patients. Each group presents unique needs and characteristics, playing a crucial role in shaping the overall market dynamics. Pediatric Patients often face challenges with diagnosis and treatment adherence, making this demographic vital for future treatment innovations. Meanwhile, Adult Patients typically dominate the market due to the higher prevalence of bradykinin-mediated conditions within this age group, driven by lifestyle factors and genetic predispositions.

The Geriatric Patients segment is also significant as it is increasingly impacted by this condition alongside age-related health issues, creating a demand for tailored therapeutic solutions. These demographics collectively contribute to the Bradykinin Mediated Angioedema Market growth as the industry responds to their specific treatment requirements and associated healthcare trends. Overall, the market exhibits a steady increase in interest and investment, emphasizing the importance of understanding these patient segments for future strategies and developments in the industry.With an expected continued expansion, the market is poised to address escalating healthcare needs responsibly and effectively.

### **Bradykinin Mediated Angioedema Market Regional Insights**

The Bradykinin Mediated Angioedema Market revenue is witnessing substantial growth across different regions, with North America holding a significant market share of 0.42 USD Billion in 2023, projected to increase to 1.05 USD Billion by 2032. This dominance can be attributed to advanced healthcare infrastructure and a high prevalence of angioedema cases. Europe follows as another key region, with market values of 0.25 USD Billion in 2023 and 0.65 USD Billion in 2032, benefiting from a strong regulatory framework and research initiatives.

The APAC region, though smaller, shows promising growth potential, escalating from 0.15 USD Billion in 2023 to 0.45 USD Billion by 2032, driven by rising healthcare awareness and investments in treatment options.

South America and MEA represent the emerging markets in the Bradykinin Mediated Angioedema Market industry, with values of 0.06 USD Billion and 0.05 USD Billion in 2023, respectively, reflecting a growth trajectory as healthcare access improves. These regions present significant opportunities to tap into increasing demand for effective treatments as more awareness of this condition grows. Bradykinin Mediated Angioedema Market statistics indicate a clear trend toward increased investments, highlighting the importance of continuously expanding healthcare access and innovation across these diverse regions.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Bradykinin Mediated Angioedema Market Key Players and Competitive Insights**

The Bradykinin Mediated Angioedema Market is characterized by a dynamic competitive landscape, driven by the increasing prevalence of angioedema conditions and the growing understanding of bradykinin's role in these diseases. As research advances, companies are focusing on the development of innovative therapeutic options that cater to the specific needs of patients suffering from angioedema. 

The market includes a variety of stakeholders ranging from pharmaceutical giants to specialized biotechnology firms, all vying for a significant share. Companies are employing strategies such as collaborations, mergers, and acquisitions to enhance their product portfolios and extend their market reach. The landscape is also marked by intense competition where product differentiation and effective marketing strategies play crucial roles in capturing consumer attention.

Takeda Pharmaceutical Company holds a prominent position in the Bradykinin Mediated Angioedema Market, showcasing its strengths through a robust pipeline of products and research initiatives targeted specifically at treating angioedema. The company is recognized for its commitment to patient-centric solutions, which is reflected in its innovative approaches to treatment development. Takeda's strategy emphasizes the importance of addressing patient needs and improving health outcomes, enabling it to maintain a competitive edge in the market. 

Additionally, its extensive network and experience in managing complex therapeutic areas bolster its operational capabilities and market presence. By investing in research and development, Takeda continually seeks to enhance its therapeutic offerings, solidifying its reputation in the bradykinin-mediated angioedema segment.

Novo Nordisk has also established itself as a key player in the Bradykinin Mediated Angioedema Market, bringing valuable expertise and resources to the table. The company is known for its strong focus on innovation, particularly in developing effective therapies that manage rare and chronic conditions like bradykinin-mediated angioedema. Novo Nordisk adopts a holistic approach to treatment by incorporating advancements in biotechnology and leveraging its extensive knowledge of patient care. Its commitment to research allows for the continuous evolution of its product offerings, positioning the company effectively against its competitors. 

Furthermore, Novo Nordisk's strategic partnerships and collaborations enhance its ability to introduce novel solutions to the market, ensuring it meets the demands and needs of patients suffering from angioedema in an increasingly competitive environment.

### **Key Companies in the Bradykinin Mediated Angioedema Market Include**

- Takeda Pharmaceutical Company
- Novo Nordisk
- Biocryst Pharmaceuticals
- GSK
- Bayer AG
- Pfizer Inc
- CSL Limited
- [**Amgen Inc**](https://www.amgen.com/products)
- Regeneron Pharmaceuticals
- Roche Holding AG
- Eli Lilly and Company
- Merck and Co
- Sanofi
- AstraZeneca
- Shire plc

## Bradykinin Mediated Angioedema Market Industry Developments

- **Q2 2025: Pharvaris Presents Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025** Pharvaris presented new clinical data on deucrictibant, an oral bradykinin B2 receptor antagonist, at the EAACI Congress 2025, showing significant attack reduction and improved quality of life for hereditary angioedema patients. The company also announced advancement into Phase 3 trials for both prophylactic and on-demand treatment indications.
- **Q2 2025: Pharvaris AGM 2025: A Pivotal Moment for Braking into the Angioedema Market** Pharvaris N.V. announced that its lead drug candidate, deucrictibant, is approaching pivotal clinical readouts and regulatory milestones, with the company preparing for its June 27, 2025 Annual General Meeting. The oral therapy targets both hereditary and acquired bradykinin-mediated angioedema, with Phase 3 trials underway.
- **Q1 2025: Pharvaris Outlines 2025 Strategic Priorities** Pharvaris announced the initiation of CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema attacks, and confirmed ongoing preparations for regulatory submission and commercialization pending trial results.

## **Bradykinin Mediated Angioedema Market Segmentation Insights**

### **Bradykinin Mediated Angioedema Market Type Outlook**

- Hereditary Angioedema
- Acquired Angioedema
- Idiopathic Angioedema

### **Bradykinin Mediated Angioedema Market Treatment Options Outlook**

- C1-Inhibitor Replacement Therapy
- Bradykinin B2 Receptor Antagonists
- Kalinate Therapy
- Antifibrinolytic Agents

### **Bradykinin Mediated Angioedema Market Route of Administration Outlook**

- Subcutaneous
- Intravenous
- Oral

### **Bradykinin Mediated Angioedema Market Patient Demographics Outlook**

- Pediatric Patients
- Adult Patients
- Geriatric Patients

### **Bradykinin Mediated Angioedema Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 增加研究资金

针对由缓激肽介导的血管性水肿的研究资金分配是缓激肽介导的血管性水肿市场的关键驱动因素。政府和私人组织正越来越多地投资于旨在理解血管性水肿的基本机制和开发有效治疗方法的研究。这一资金的涌入预计将加快创新的步伐，导致新治疗药物的发现。此外，随着研究的进展，新的生物标志物的识别可能会提高诊断的准确性和治疗的有效性。对推动该领域知识进步的承诺可能会增强缓激肽介导的血管性水肿市场的增长轨迹。

### 治疗选择的进展

针对由缓激肽介导的血管性水肿的治疗方法的创新正在显著影响缓激肽介导的血管性水肿市场。新疗法的引入，如C1抑制剂替代疗法和缓激肽受体拮抗剂，已经改变了治疗范式。这些进展不仅改善了患者的治疗效果，还提升了整体市场格局。例如，新药的批准导致治疗选择的激增，满足了不同患者的需求。随着市场的不断发展，靶向疗法的开发可能会吸引更多投资，从而促进缓激肽介导的血管性水肿市场的增长。

### 发展患者倡导团体

专门针对由缓激肽介导的血管性水肿的患者倡导团体的出现正在促进缓激肽介导的血管性水肿市场的意识和支持。这些组织在教育患者和医疗专业人员有关该病症方面发挥着关键作用，从而促进及时的诊断和治疗。他们在提高意识方面的努力可能会导致对疗法的需求增加，因为更多的人寻求医疗帮助。此外，这些团体通常与制药公司合作，促进临床试验，这可以加快新治疗方法的开发。患者倡导的影响可能会增强缓激肽介导的血管性水肿市场的可见性。

### 药物开发的监管激励

监管机构越来越多地为开发与缓激肽介导的血管性水肿相关的治疗提供激励，这成为缓激肽介导的血管性水肿市场的重要驱动力。孤儿药物认定和快速审批等举措旨在鼓励制药公司投资于这一小众市场。这些监管框架不仅减少了将新疗法推向市场所需的时间和成本，还增强了该行业对投资者的吸引力。随着越来越多的公司进入市场，竞争格局可能会发生变化，从而为遭受缓激肽介导的血管性水肿的患者提供更广泛的治疗选择。

### 血管性水肿发生率上升

随着介导性血管性水肿的缓慢激增，血管性水肿市场的一个显著驱动因素。最近的研究表明，遗传性血管性水肿的发生率约为每5万人中有1人，而获得性形式则越来越受到关注。这一病例的增加需要有效的治疗选择，从而推动市场增长。随着对该病症的认识不断提高，医疗服务提供者更有可能对患者进行诊断和治疗，进一步促进市场的扩展。不断增长的患者群体预计将推动对创新疗法的需求，这可能导致对血管性水肿市场内研究和开发的投资增加。

## Future Outlook

布拉迪激肽介导的血管性水肿市场预计将在2024年至2035年间以11.62%的年复合增长率增长，推动因素包括日益增强的意识、创新疗法和不断增加的患者群体。

**New opportunities:**

- 针对个性化治疗方案的靶向生物制剂开发。 远程患者监测的远程医疗服务扩展。 对医疗专业人员进行血管性水肿管理的教育项目投资。

到2035年，市场预计将实现显著增长，定位为创新治疗解决方案的领导者。

## Segment Insights

### 按类型：遗传性血管性水肿（最大）与获得性血管性水肿（增长最快）

在布拉迪激肽介导的血管性水肿市场中，不同类型血管性水肿的市场份额分布显示出遗传性血管性水肿的显著主导地位。由于人们对遗传性疾病的认识和诊断率不断提高，加上针对遗传性疾病的治疗方案的进步，该细分市场继续占据最大的市场份额。相反，获得性血管性水肿正在迅速崛起，因其不同的病因和诱因受到医疗服务提供者的越来越多的关注，从而导致研究和治疗机会的扩大。

遗传性血管性水肿（显性）与获得性血管性水肿（新兴）

遗传性血管性水肿仍然是布拉迪激肽介导的血管性水肿市场中的主导部分，因其遗传特性和成熟的治疗方案，包括针对这种慢性病症的特定疗法。患者通常需要长期管理以预防发作，这维持了对专业治疗的需求。另一方面，获得性血管性水肿正作为一个重要部分崛起，受到对该病症的临床理解和诊断的提升驱动。由于药物或相关疾病等各种因素导致的病例数量不断增加，促使医疗系统更加关注针对获得性病例的个性化干预，从而塑造了一个有利于创新疗法开发的竞争格局。

### 按治疗选项：C1-抑制剂替代疗法（最大）与缓激肽B2受体拮抗剂（增长最快）

在布拉迪激肽介导的血管性水肿市场中，市场份额分布显示C1抑制剂替代疗法是最大的细分市场，占据了整体市场的相当一部分。这一确立的地位得益于其在恢复C1抑制剂水平方面的有效性，使其成为临床医生和患者的首选。另一方面，布拉迪激肽B2受体拮抗剂正在迅速获得关注，成为增长最快的治疗选择，因为其新颖的机制直接靶向布拉迪激肽受体，从而吸引了医疗专业人士和制药公司的兴趣。该细分市场的增长趋势受到对布拉迪激肽介导的血管性水肿市场认识不断提高和创新治疗方法的显著影响。血管性水肿发病率上升、药物配方的进步以及新疗法的临床试验扩展等因素正在推动现有和新兴治疗选择的增长。旨在改善患者结果的治疗方案和支持性指南的扩展进一步鼓励了这些疗法在临床实践中的采用。

C1-抑制剂替代疗法（显性）与布拉迪激肽B2受体拮抗剂（新兴）

C1-抑制剂替代疗法被认为是布拉迪激肽介导的血管性水肿市场的主要治疗选择，因为它的长期使用和确立的疗效。它有效地替代了患者体内缺乏的C1抑制剂，解决了该病症的根本原因。这种治疗在急性和预防性场合中常被优先选择，使其成为治疗方案中的重要组成部分。相反，布拉迪激肽B2受体拮抗剂代表了一种新兴的治疗类别，针对布拉迪激肽受体，提供了不同的作用机制。它们的快速发展突显了对靶向疗法日益增长的兴趣，并为可能对传统疗法反应不佳的患者提供了潜在的替代方案。正在进行的研究和临床试验预计将在未来几年显著增强它们的市场存在。

### 按给药途径：皮下（最大）与静脉注射（增长最快）

在布拉迪激肽介导的血管性水肿市场中，给药途径在治疗偏好和疗效中起着关键作用。皮下给药目前占据最大的市场份额，因为它使用方便，患者依从性高，并且能够有效地递送治疗药物。尽管静脉给药的市场份额较低，但由于其快速起效，尤其是在急性情况下，正在获得关注，满足了一部分严重表现患者的需求。

给药方法：皮下（主导）与静脉（新兴）

在布拉迪激肽介导的血管性水肿市场中，皮下给药途径仍然占主导地位，因为它为患者提供了一种更简单、侵入性更小的选择，适合家庭使用场景。这种方法使个人能够在最少的专业监督下管理他们的病情。另一方面，静脉给药作为一种重要的替代方案正在兴起，特别是对于需要在急性血管性水肿发作中获得即时缓解的患者。这种方法确保药物迅速进入血液，导致更快的效果，这在危及生命的情况下至关重要。

### 按患者人口统计：成人患者（最大）与儿童患者（增长最快）

在布拉迪激肽介导的血管性水肿市场中，人口分布显示成人患者构成了最大的群体，这反映了他们更高的慢性病患病率，这些慢性病可能导致这种类型的血管性水肿。同时，儿童患者代表了增长最快的群体，这得益于对儿童布拉迪激肽介导疾病的认识提高和诊断改善，以及为儿童提供的更好的治疗选择。随着医疗服务提供者专注于早期干预，儿童群体报告的病例显著增加。这一增长还受到对儿童健康洞察的倡导以及对理解儿童群体血管性水肿的研究参与度提高的推动。这一转变突显了为不同年龄组量身定制治疗方案在管理这种疾病中的重要性。

成人患者（主导）与老年患者（新兴）

成年患者在布拉迪激肽介导的血管性水肿市场中占主导地位，主要是由于他们更高的易感性和现有健康状况可能加重血管性水肿症状。成年群体被视为制药开发的主要焦点，治疗的进展广泛满足他们的需求。相比之下，老年患者作为一个重要的人群，受到老龄化人口和相关健康复杂性的驱动。虽然他们目前可能占有较小的市场份额，但对非典型血管性水肿挑战的日益认识以及对老年人专门治疗选择的需求可能会增强他们的市场存在。随着医学研究的发展，针对老年患者的个性化疗法将变得至关重要，以应对与老龄化相关的独特反应和相互作用。

## Regional Market Share Analysis

### 北美：治疗的领先市场

北美是布拉迪激肽介导的血管性水肿市场最大的市场，占全球市场份额的约60%。该地区的增长受到对该病症认识的提高、治疗选择的进步以及支持性监管框架的推动。FDA对新疗法的批准催化了市场扩张，市场对有效管理解决方案的需求不断增长。美国是主要贡献者，来自武田药品工业株式会社和BioCryst制药公司等关键参与者的重大投资推动了市场发展。加拿大也发挥着重要作用，专注于改善医疗保健的可及性和治疗选择。竞争格局由一系列成熟公司和新兴参与者构成，促进了该领域的创新与合作。

### 欧洲：具有潜力的新兴市场

欧洲正在经历布拉迪激肽介导的血管性水肿市场的显著增长，占全球市场份额的约25%。该地区的增长受到患者意识提高、生物技术进步和支持性医疗政策的推动。监管机构积极促进研究与开发，预计将增强成员国的治疗可用性和可及性。德国、法国和英国等领先国家处于前沿，拥有Pharming Group N.V.和Sobi AB等关键参与者的强大存在。竞争格局正在演变，制药公司与研究机构之间的合作旨在开发创新疗法。欧洲药品管理局继续支持增强患者治疗选择的倡议。

### 亚太地区：快速发展的医疗保健行业

亚太地区正在成为布拉迪激肽介导的血管性水肿市场的重要参与者，占全球市场份额的约10%。增长受到医疗保健支出增加、对罕见疾病认识提高以及创新疗法引入的推动。日本和澳大利亚等国正在引领这一潮流，受益于鼓励该领域研究与开发的有利监管环境。日本是Eisai Co., Ltd.等关键参与者的所在地，而澳大利亚则见证了临床试验和合作伙伴关系的激增，旨在增强治疗选择。竞争格局由本地和国际公司混合构成，促进了创新的合作环境。随着该地区的持续发展，对有效管理解决方案的需求预计将显著上升。

### 中东和非洲：未开发的市场机会

中东和非洲地区目前是布拉迪激肽介导的血管性水肿市场最小的市场，占全球市场份额的约5%。然而，该地区提供了未开发的增长机会，受到医疗保健投资增加和罕见疾病患病率上升的推动。各国政府开始认识到解决这些病症的重要性，导致医疗政策和研究资助的改善。南非和阿联酋等国正在成为市场的关键参与者，国际制药公司对该市场的兴趣日益增长。竞争格局仍在发展中，本地公司与全球实体合作以增强治疗可用性。随着意识的提高，对有效疗法的需求预计将增长，为未来市场扩张铺平道路。

## Competitive Benchmarking

布拉迪激肽介导的血管性水肿市场的特点是动态的竞争格局，受到对该病症认识的提高和治疗选择的进步的推动。主要参与者如武田制药公司（日本）、BioCryst制药公司（美国）和Pharming集团（荷兰）处于前沿，各自采取不同的策略以增强其市场存在感。武田（日本）专注于通过开发新疗法来推动创新，而BioCryst制药公司（美国）则强调战略合作伙伴关系以增强其研究能力。Pharming集团（荷兰）似乎专注于扩大其全球足迹，特别是在新兴市场，从而塑造一个日益合作但竞争激烈的环境。

在商业策略方面，公司正在本地化生产并优化供应链，以提高效率和对市场需求的响应。市场结构适度分散，既有成熟的参与者，也有新兴的生物技术公司。这种分散性允许对治疗和患者护理采取多样化的方法，而主要参与者的集体影响力推动了创新和竞争差异化。

2025年8月，武田制药公司（日本）宣布与一家领先的研究机构达成战略合作，以加速其下一代血管性水肿疗法的开发。这一合作关系可能会增强武田的研究能力，并加快创新治疗的推出，使公司在治疗领域中处于领先地位。

2025年9月，BioCryst制药公司（美国）推出了一个新的数字平台，旨在改善患者参与和遵循治疗方案的情况。这一举措不仅反映了公司对以患者为中心的护理的承诺，还表明了医疗行业向数字化转型的更广泛趋势，这可能会提高治疗效果和患者满意度。

2025年7月，Pharming集团（荷兰）获得了其最新产品的监管批准，该产品旨在治疗遗传性血管性水肿，标志着其产品管道中的一个重要里程碑。这一批准预计将加强Pharming的市场地位，并扩大其治疗产品，可能会增加其在竞争格局中的份额。

截至2025年10月，布拉迪激肽介导的血管性水肿市场的当前趋势越来越多地受到数字化、可持续性和人工智能在治疗方案中整合的定义。主要参与者之间的战略联盟正在塑造市场，促进创新并增强供应链的可靠性。展望未来，竞争差异化可能会从传统的基于价格的竞争转向对技术进步和创新治疗解决方案的关注，强调在快速变化的市场中灵活性和响应能力的重要性。

## Recent News & Developments

- **2025年第二季度：Pharvaris在2025年EAACI大会上展示了关于德克立替班在介导性血管性水肿中的有希望的数据** Pharvaris在2025年EAACI大会上展示了关于德克立替班（口服的布拉迪激肽B2受体拮抗剂）的新临床数据，显示出显著的发作减少和遗传性血管性水肿患者的生活质量改善。该公司还宣布进入针对预防和按需治疗适应症的第三阶段临床试验。
- **2025年第二季度：Pharvaris 2025年股东大会：进入血管性水肿市场的关键时刻** Pharvaris N.V.宣布其主要药物候选者德克立替班即将迎来关键的临床结果和监管里程碑，公司正在为2025年6月27日的年度股东大会做准备。这种口服疗法针对遗传性和获得性介导性血管性水肿，目前正在进行第三阶段临床试验。
- **2025年第一季度：Pharvaris概述2025年战略优先事项** Pharvaris宣布启动CHAPTER-3，这是德克立替班用于预防遗传性血管性水肿发作的关键第三阶段研究，并确认正在为监管提交和商业化做准备，待试验结果确认。

## Report Scope

| 2024年市场规模 | 1.154（十亿美元） |
| --- | --- |
| 2025年市场规模 | 1.288（十亿美元） |
| 2035年市场规模 | 3.868（十亿美元） |
| 复合年增长率（CAGR） | 11.62%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 靶向疗法和个性化医学的进展增强了布拉迪激肽介导的血管性水肿市场的治疗选择。 |
| 主要市场动态 | 靶向疗法的需求上升推动了布拉迪激肽介导的血管性水肿市场的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，布拉迪激肽介导的血管性水肿的市场估值预计是多少？**
A: 预计到2035年，布拉迪激肽介导的血管性水肿市场估值将达到38.68亿美元。

**Q: 2024年，布拉迪激肽介导的血管性水肿的市场估值是多少？**
A: 2024年，布拉迪激肽介导的血管性水肿的市场估值为11.54亿美元。

**Q: 在2025年至2035年的预测期内，布拉迪激肽介导的血管性水肿市场的预期CAGR是多少？**
A: 在2025年至2035年的预测期内，布拉迪激肽介导的血管性水肿市场的预期CAGR为11.62%。

**Q: 在布拉迪激肽介导的血管性水肿市场中，哪些公司是关键参与者？**
A: 在布拉迪激肽介导的血管性水肿市场中，主要参与者包括武田药品工业株式会社、CSL Behring LLC 和Pharming Group N.V.

**Q: 市场上主要的血管性水肿细分类型有哪些？**
A: 血管性水肿的主要类型包括遗传性血管性水肿、获得性血管性水肿和特发性血管性水肿。

**Q: 2024年遗传性血管性水肿的市场规模是多少？**
A: 2024年遗传性血管性水肿的市场规模为4.62亿美元。

**Q: 对于由缓激肽介导的血管性水肿，有哪些治疗选择？**
A: 可用的治疗选项包括C1抑制剂替代疗法、布拉迪激肽B2受体拮抗剂和抗纤溶药物。

**Q: 到2035年，C1抑制剂替代疗法的预计市场规模是多少？**
A: 预计到2035年，C1抑制剂替代疗法的市场规模将达到15.77亿美元。

**Q: 给药途径如何影响由缓激肽介导的血管性水肿市场？**
A: 给药途径包括皮下、静脉和口服，预计到2035年皮下给药将达到16.15亿美元。

**Q: 在布拉迪激肽介导的血管性水肿市场中考虑了哪些人口细分？**
A: 人口细分包括儿科患者、成人患者和老年患者，预计到2035年，成人患者将达到19.49亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/bradykinin-mediated-angioedema-market-36162*